UniSuper Management Pty Ltd Trims Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UniSuper Management Pty Ltd reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 57.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,499 shares of the company's stock after selling 10,080 shares during the period. UniSuper Management Pty Ltd's holdings in IDEXX Laboratories were worth $3,100,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock valued at $1,138,732,000 after purchasing an additional 40,349 shares during the period. Franklin Resources Inc. increased its position in IDEXX Laboratories by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after acquiring an additional 34,305 shares during the period. American Century Companies Inc. raised its stake in IDEXX Laboratories by 30.9% during the 4th quarter. American Century Companies Inc. now owns 809,814 shares of the company's stock valued at $334,810,000 after acquiring an additional 191,385 shares during the last quarter. Amundi lifted its position in IDEXX Laboratories by 8.1% during the 4th quarter. Amundi now owns 758,669 shares of the company's stock worth $328,018,000 after acquiring an additional 56,837 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of IDEXX Laboratories by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company's stock valued at $219,823,000 after purchasing an additional 16,213 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Remove Ads

IDEXX Laboratories Price Performance

IDXX traded down $17.01 during trading on Thursday, reaching $409.24. 206,590 shares of the stock were exchanged, compared to its average volume of 583,296. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The company has a market capitalization of $33.17 billion, a price-to-earnings ratio of 38.35, a P/E/G ratio of 3.41 and a beta of 1.39. The business's 50 day moving average price is $436.82 and its two-hundred day moving average price is $441.34. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IDXX. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday, March 25th. Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.